AIHealthcare Analytics

Overview

The global AI in drug repurposing market is projected to reach USD 10.56 billion by 2035, growing at a compound annual growth rate (CAGR) of 23.4%, according to Healthcare Foresights analysis (Article 22, Yahoo Finance). This represents one of the highest growth rates in any healthcare AI subsector, driven by the pharmaceutical industry's need to reduce drug development timelines and costs.

Market Drivers

Drug repurposing — identifying new therapeutic uses for existing approved drugs — benefits substantially from AI's ability to analyze large multimodal datasets including genomic data, electronic health records, published literature, and molecular interaction databases. AI can identify non-obvious connections between existing drug mechanisms and disease pathways that would be prohibitively time-consuming to discover through traditional experimental methods. The COVID-19 pandemic demonstrated the value of rapid repurposing, accelerating industry investment in AI-based approaches.

Competitive Landscape

The drug repurposing AI market includes pharmaceutical companies building internal capabilities, specialized AI drug discovery startups, and cloud platform providers offering repurposing-as-a-service. Key competitive dimensions include the breadth and quality of proprietary training data, the interpretability of AI-generated hypotheses, and the ability to integrate with wet-lab validation workflows. The 23.4% CAGR forecast suggests the market is in an early growth phase with significant consolidation likely over the 2026–2035 period.